State Street Holds 5.1% Of CareDx Without Seeking To Influence Control
The passive holding totaled 2,623,064 shares, alongside CareDx's higher 2026 revenue outlook.
State Street reported a 5.1% stake in CareDx, which sells tests and services for transplant patients, without seeking to influence the company's control. The passive ownership disclosure filed Tuesday put its holding at 2,623,064 common shares.
Ownership Without A Control Campaign
State Street certified that the shares were bought and held as part of its ordinary business, rather than to change or influence CareDx's control. The ownership figures refer to September 30, 2026, rather than the filing date.
State Street had shared voting power over 2,505,109 shares and sole voting power over none. Its reported 5.1% uses the disclosure's beneficial-ownership measure for CareDx's common-stock class.
A Higher Sales Outlook
CareDx reported third-quarter revenue of $139.4 million and net income of $19.3 million. The company raised its 2026 revenue outlook to $520 million to $530 million.
Zacks Equity Research's consensus earnings estimate for CareDx increased 110.6% over three months. Zacks attributed its upgrade to a Strong Buy ranking to those upward revisions; that rating is the research firm's assessment.
CareDx had a market value of $4.4 billion as of 7:17 a.m. ET Tuesday.
Transplant Tests Anchor CareDx's Business
CareDx's blood tests check heart, kidney and lung transplant recipients for injury or rejection without an invasive procedure. It also sells donor-matching laboratory kits, transplant-center software and specialized pharmacy services.
During 2025, its Brisbane, California laboratory performed approximately 200,000 commercial tests. Its software was used by more than 170 U.S. transplant centers, according to its annual report for 2025.
Medicare supplied approximately 46% of testing-services revenue in 2025. As of December 31, 2025, substantially all revenue came from the United States and Europe, and CareDx operated as a single reportable segment.
Sources
- SCHEDULE 13G — STATE STREET CORPORATION re: CAREDX INC (CDNA) — SEC EDGAR
- CareDx (CDNA) Upgraded to Strong Buy: Here's What You Should Know — Yahoo Finance
- CareDx Inc. (NASD:CDNA) : Articles :: Law360 — law360.com
- Should Earnings Upgrade Require Action From CareDx Stock Investors? — Yahoo Finance
- Cathie Wood's ARK Invest Buys More Dinner-Plate-Size AI Chips | Investor's Business Daily — investors.com
- CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) — businesswire.com